Tags

Type your tag names separated by a space and hit enter

[Efficacy and safety of neuroprotection in patients with primary open-angle glaucoma].
Vestn Oftalmol 2019; 135(2):83-92VO

Abstract

Elevated intraocular pressure (IOP) is considered one of the main factors in the development and progression of primary open-angle glaucoma (POAG). The main schemes of drug treatment and cell protection from glaucomatous damage are aimed particularly at reducing IOP. However, it is possible for the disease to progress with normalized IOP. This determines the need to search for drugs that would affect other pathogenetic links of the progression of POAG.

PURPOSE

To study the effect of 'Cytoflavin' drug on the stabilization of glaucomatous optic neuropathy in patients with POAG.

MATERIAL AND METHODS

The study included 103 patients with initial or developed POAG. Patients were randomized into two groups using random numbers: the control group patients (n=50) receiving standard conservative treatment, and the main group (n=53), where patients received the combined drug with metabolic action 'Cytoflavin'. In addition to standard ophthalmological studies, all patients underwent biological, electrophysiological, perimetric, structural topographic, laboratory and sociological examinations before and after the treatment.

RESULTS

By the end of the 3rd month of the treatment, the patients of the main group showed positive dynamics of the amplitude and phase characteristics of bioelectric activity of the retina, improvement in the total sensitivity of the retina for central field of view. Cytoflavin contributed to reducing the rate of progression of glaucoma according to optical coherence tomography: stabilization of the thickness of the nerve fiber layer, reduction of the rate of global and focal loss of retinal ganglion cells. In patients of the main group, by the end of the 3rd month, the severity of oxidative stress has significantly reduced and the antioxidant defense improved. On the background of stabilized glaucomatous process, a subjective improvement in general and psycho-emotional health, increased confidence in the success of the therapy and thus the improved the quality of life was observed in comorbid patients of the main group.

CONCLUSION

Cytoflavin acts on the mechanisms that enhance the protection of the retina against the effects of reperfusion injury and oxidative stress, contributes to the metabolic adaptation of neurons and leads to a more favorable variant of POAG.

Authors+Show Affiliations

Regional Ophthalmologic Dispensary, 118/1 Kholodilnaja St., Tyumen, Russian Federation, 625048; West-Siberian Institute of Postgraduate Medical Education, 5/11 Prokopiya Artamonova St., Tyumen, Russian Federation, 625051.Hospital for war veterans, 47/1 Volodarsky St., Tyumen, Russian Federation, 625000.Regional Ophthalmologic Dispensary, 118/1 Kholodilnaja St., Tyumen, Russian Federation, 625048.Regional Ophthalmologic Dispensary, 118/1 Kholodilnaja St., Tyumen, Russian Federation, 625048.Regional Ophthalmologic Dispensary, 118/1 Kholodilnaja St., Tyumen, Russian Federation, 625048.Tyumen State Medical University, 54 Odesskaya St., Tyumen, Russian Federation, 625023.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

rus

PubMed ID

31215538

Citation

Malishevskaya, T N., et al. "[Efficacy and Safety of Neuroprotection in Patients With Primary Open-angle Glaucoma]." Vestnik Oftalmologii, vol. 135, no. 2, 2019, pp. 83-92.
Malishevskaya TN, Yusupov AR, Shatskikh SV, et al. [Efficacy and safety of neuroprotection in patients with primary open-angle glaucoma]. Vestn Oftalmol. 2019;135(2):83-92.
Malishevskaya, T. N., Yusupov, A. R., Shatskikh, S. V., Antipina, N. A., Klindyuk, T. S., & Bogdanova, D. S. (2019). [Efficacy and safety of neuroprotection in patients with primary open-angle glaucoma]. Vestnik Oftalmologii, 135(2), pp. 83-92. doi:10.17116/oftalma201913502183.
Malishevskaya TN, et al. [Efficacy and Safety of Neuroprotection in Patients With Primary Open-angle Glaucoma]. Vestn Oftalmol. 2019;135(2):83-92. PubMed PMID: 31215538.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Efficacy and safety of neuroprotection in patients with primary open-angle glaucoma]. AU - Malishevskaya,T N, AU - Yusupov,A R, AU - Shatskikh,S V, AU - Antipina,N A, AU - Klindyuk,T S, AU - Bogdanova,D S, PY - 2019/6/20/entrez PY - 2019/6/20/pubmed PY - 2019/8/23/medline KW - cytoflavin KW - glaucoma KW - ischemic preconditioning SP - 83 EP - 92 JF - Vestnik oftalmologii JO - Vestn Oftalmol VL - 135 IS - 2 N2 - : Elevated intraocular pressure (IOP) is considered one of the main factors in the development and progression of primary open-angle glaucoma (POAG). The main schemes of drug treatment and cell protection from glaucomatous damage are aimed particularly at reducing IOP. However, it is possible for the disease to progress with normalized IOP. This determines the need to search for drugs that would affect other pathogenetic links of the progression of POAG. PURPOSE: To study the effect of 'Cytoflavin' drug on the stabilization of glaucomatous optic neuropathy in patients with POAG. MATERIAL AND METHODS: The study included 103 patients with initial or developed POAG. Patients were randomized into two groups using random numbers: the control group patients (n=50) receiving standard conservative treatment, and the main group (n=53), where patients received the combined drug with metabolic action 'Cytoflavin'. In addition to standard ophthalmological studies, all patients underwent biological, electrophysiological, perimetric, structural topographic, laboratory and sociological examinations before and after the treatment. RESULTS: By the end of the 3rd month of the treatment, the patients of the main group showed positive dynamics of the amplitude and phase characteristics of bioelectric activity of the retina, improvement in the total sensitivity of the retina for central field of view. Cytoflavin contributed to reducing the rate of progression of glaucoma according to optical coherence tomography: stabilization of the thickness of the nerve fiber layer, reduction of the rate of global and focal loss of retinal ganglion cells. In patients of the main group, by the end of the 3rd month, the severity of oxidative stress has significantly reduced and the antioxidant defense improved. On the background of stabilized glaucomatous process, a subjective improvement in general and psycho-emotional health, increased confidence in the success of the therapy and thus the improved the quality of life was observed in comorbid patients of the main group. CONCLUSION: Cytoflavin acts on the mechanisms that enhance the protection of the retina against the effects of reperfusion injury and oxidative stress, contributes to the metabolic adaptation of neurons and leads to a more favorable variant of POAG. SN - 0042-465X UR - https://www.unboundmedicine.com/medline/citation/31215538/[Efficacy_and_safety_of_neuroprotection_in_patients_with_primary_open-angle_glaucoma] L2 - http://www.diseaseinfosearch.org/result/9163 DB - PRIME DP - Unbound Medicine ER -